Gemphire Announces Positive Results for Gemcabene in

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
101
Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study

LIVONIA, Mich., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (NASDAQ: GEMP ) today announced expanded utility for gemcabene with compelling preclinical data results demonstrating proof of concept efficacy in a well-established animal model of nonalcoholic steatohepatitis (NASH).  Gemphire plans to initiate clinical development of gemcabene in NASH/nonalcoholic fatty liver disease (NAFLD) with a Phase 2 trial (AZURE-1) in 2017.  There are currently no treatments for NAFLD and NASH approved by the FDA.  Gemcabene has the potential to add complementary mechanisms that lower both triglycerides (fat) and inflammation, which we believe prevents the progression of fibrosis, particularly for diabetic and obese people, which represent a large portion of the NASH patients.

The study investigated the effects of gemcabene on the widely used STAM TM mouse model of NASH/fibrosis.  In this model, diabetic mice that are fed a high fat diet rapidly develop fatty liver disease.  When the mice were administered gemcabene, a hepatoprotective effect preventing liver disease progression was observed, in contrast to the control group.  Specifically, gemcabene treatment resulted in a significant lowering of the liver NAFLD activity score (NAS), a composite measure of fatty liver disease comprised of measures of steatosis, inflammation, and hepatocyte ballooning.  Progression of liver fibrosis was also significantly reduced with gemcabene treatment.  Additionally, hepatic gene expression and plasma markers indicative of inflammation (e.g., CRP and CCR2/CCR5), and lipid modulation (e.g., ApoC-III) were significantly reduced as were other markers.  The complete NASH preclinical results will be submitted for publication in 2017.  

“We are delighted to share the results of our preclinical study demonstrating exciting proof of concept data for gemcabene in NASH, including its anti-fibrotic and anti-inflammatory features,” said Mina Sooch, President and Chief Executive Officer of Gemphire.  “Moving forward with Phase 2 clinical development in NAFLD/NASH is now a key priority for us and is in line with our strategy to expand the breadth of indications for gemcabene beyond the 14 million dyslipidemia patients in need of cholesterol and triglyceride reduction that we are also pursuing.  Given the high prevalence of NAFLD and those that progress to NASH in the developed world, estimated at 6 million in the US, and only projected to increase further given the current trends in diabetes and obesity, we see it as a sizable additional opportunity to the cardiovascular disease market.” 

“There is an urgent need for a safe pharmacologic therapy that can regress or prevent progression of liver damage and fibrosis in NAFLD/NASH patients,” said Dr. Charles L. Bisgaier, Co-founder and Chief Scientific Officer of Gemphire.  “Historical preclinical and clinical studies have shown significant lowering in plasma of LDL-C, triglycerides and CRP when given oral, once-daily gemcabene.  Gemcabene’s dual mechanism of action includes inhibition of hepatic de novo cholesterol and triglyceride synthesis.  Gemcabene also reduces hepatic apoC-III and CRP gene expression.  We believe these properties of gemcabene are well-suited to address the key functional aspects of NAFLD/NASH and to target the underlying disease pathology.”

Gemphire intends to conduct a Phase 2 trial (AZURE-1) to evaluate gemcabene’s therapeutic effects in NAFLD/NASH patients. Our current accepted IND for dyslipidemia indications is with the Metabolism and Endocrine Division of the FDA, and we will be submitting a new IND for the NAFLD/NASH indication to the GI Division.

“We are excited by our plan to launch our clinical development program for gemcabene in NAFLD/NASH in 2017,” said Dr. Lee Golden, Chief Medical Officer at Gemphire.  “We already have a comprehensive data set on gemcabene from 895 subjects across 18 trials.  We believe these results should enable us to initiate a Phase 2 proof of concept trial in NAFLD/NASH.  In prior studies Gemcabene has been shown to be well tolerated and has not shown any liver toxicities at doses between 150 to 900 mg up to 12 weeks as monotherapy or when combined with statins and other drugs. Like many other diseases we believe that NAFLD/NASH patients will require therapies targeting several mechanisms of action.  In clinical trials to date, gemcabene has also shown a low likelihood for drug-drug interactions, particularly with statins that are widely used in in diabetic and dyslipidemic patients, which we believe adds to gemcabene’s potential value in this disease.”

About NAFLD/NASH Nonalcoholic steatohepatitis (NASH) is a severe disease of the liver caused by inflammation and a buildup of fat in the organ.  In the United States, NASH affects up to approximately 2-5% of the population.  An additional 10-30% of Americans have fat in their liver, but no inflammation or liver damage, a condition called NAFLD or “fatty liver.”  The underlying cause of NASH is unclear, but it most often occurs in persons who are middle-aged and overweight or obese.  Many patients with NASH have elevated serum lipids, diabetes or pre-diabetes.  Progression of NAFLD/NASH can lead to liver cirrhosis, fibrosis, hepatocellular carcinoma, liver failure and liver-related death.  Liver transplantation is currently the only treatment for advanced cirrhosis with liver failure.  At this time, there are no approved treatments by the FDA for NAFLD/NASH.

About Gemcabene Gemphire’s product candidate, gemcabene (CI-1027), is a first-in-class, once-daily, oral therapy that may be suitable for patients who are unable to achieve normal levels of LDL-C or triglycerides with currently approved therapies, primarily statins.  Gemcabene's mechanism of action is designed to enhance the clearance of very low-density lipoproteins (VLDLs) in the plasma and inhibit the production of cholesterol and triglycerides in the liver. The combined effect for these mechanisms has been clinically observed to result in a reduction of plasma VLDL-C, LDL-C, and triglycerides, as well as markedly lowering C-reactive protein.  Gemcabene is liver-directed and reduces apoC-III mRNA and plasma levels and may also inhibit acetyl-CoA carboxylase (ACC) which has applications in NASH/NAFLD.  Gemcabene has demonstrated proof of concept efficacy in a NASH STAM TM model.   Gemcabene has been tested as monotherapy and in combination with statins and other drugs in 895 subjects across 18 Phase 1 and Phase 2 clinical trials and has demonstrated promising evidence of efficacy, safety and tolerability.

About Gemphire Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular diseases, and NAFLD/NASH (nonalcoholic fatty liver disease). Gemphire has initiated 3 clinical trials for HoFH, HeFH/ASCVD, and SHTG under NCT02722408 , NCT02634151 , and NCT02944383 , respectively.  Please visit www.gemphire.com for more information.

Forward Looking Statements Any statements in this press release about Gemphire’s future expectations, plans and prospects, including statements about Gemphire’s financial prospects, future operations and sufficiency of funds for future operations, clinical development of Gemphire’s product candidate, expectations regarding future clinical trials and future expectations and plans and prospects for Gemphire and other statements containing the words "believes," "anticipates," "estimates," "expects," "intends," "plans," "predicts," "projects," "targets," "may," "potential," "will," "would," "could," "should," "continue," “scheduled” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995.  Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the success and timing of Gemphire’s regulatory submissions and pre-clinical and clinical trials; regulatory requirements or developments; changes to Gemphire’s clinical trial designs and regulatory pathways; changes in Gemphire’s capital resource requirements; Gemphire’s ability to obtain additional financing; Gemphire’s ability to successfully market and distribute its product candidate, if approved; Gemphire’s ability to obtain and maintain its intellectual property protection; and other factors discussed in the "Risk Factors" section of Gemphire’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2016, and in other filings Gemphire makes with the SEC from time to time.  In addition, the forward-looking statements included in this press release represent Gemphire’s views as of the date hereof. Gemphire anticipates that subsequent events and developments will cause Gemphire’s views to change.  However, while Gemphire may elect to update these forward-looking statements at some point in the future, Gemphire specifically disclaims any obligation to do so.  These forward-looking statements should not be relied upon as representing Gemphire’s views as of any date subsequent to the date hereof.

 

Contact: Andrew McDonald, Ph.D. LifeSci Advisors, LLC (646) 597-6987 Jeff Mathiesen, CFO Gemphire Therapeutics Inc. (734) 245-1700

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Mike Blyth’s Hall of Fame Honors a Builder’s Legacy

Updated Category News Views 147

Recognition earned in the hangar, not a boardroom Aircraft design has a ruthless way of exposing empty talk, which is why Mike Blyth’s November 11 induction into the EAA Homebuilders Hall of Fame carries real weight. The Experimental Aircraft Association’s honor, presented in the Eagle Hangar at the EAA Aviation Museum in Oshkosh, Wisconsin, recognizes a career built...

Continue Reading
New Flight Charters Puts a Cap on Winter Surprises

Updated Category News Views 115

Ice on a wing is routine; ice on an invoice is where charter customers start muttering. New Flight Charters says it will again absorb de-icing and hangar charges this winter, up to $2,500 per trip, marking the seventh consecutive season for the program. In a business where the headline quote can look tidy and the final bill can arrive wearing muddy boots, that is a...

Continue Reading
AES Clears FERC, Nearing Its December 2 Takeover Close

Updated Category News Views 50

One more regulatory gate just swung open for AES, and this deal is finally staring at the finish line instead of wandering through the usual approval swamp. The Federal Energy Regulatory Commission has issued its final order approving AES's acquisition by a consortium led by Global Infrastructure Partners, part of BlackRock, and EQT Infrastructure VI. The last major...

Continue Reading
DEFSEC Tackles Nasdaq Bid Price Hurdle with Share Move

Updated Category News Views 13

Navigating Bid Price Deficiency Issues Well, it seems DEFSEC Technologies Inc. found themselves in a tricky spot last week. A nasty gram from Nasdaq’s Listing Qualifications Department pointing out that DEFSEC's shares had dipped below that $1.00 per share requirement for too long—a full 30 business days. Now, don't panic just yet. This isn't about the shares getting...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 139

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 115

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
Norris Lake's New Kayak Fleet Propels Tourism Efforts

Updated Category News Views 217

Norris Lake Doubles Down on Water Adventures The winds of change are paddling through Norris Dam State Park as they've launched a new fleet of shiny kayaks, hoping to lure more adventure seekers into the heart of Tennessee. These ain't just boats; they're part of a bigger play by local tourism honchos hungry to pump some adrenaline—and dollars—back into the area. A...

Continue Reading
A Faded Sign Is a Quiet Leak in Storefront Demand Today

Updated Category News Views 72

Sunlight does not care what the marketing budget said. A storefront can have a decent product, a clean interior and a capable crew, then lose the first impression before anyone reaches the door because its sign looks tired. That is the plainspoken point behind FASTSIGNS' latest guidance on outdoor sign lifespan. This is not glamorous stuff, but it is operationally...

Continue Reading
MobileX's $10 Plan Puts Holiday Pressure on Wireless

Updated Category News Views 110

A sixty-dollar commitment is a small bet, but in wireless it can become a loud little nuisance for every carrier charging far more. MobileX has rolled out a Black Friday offer giving new customers 10GB of high-speed data, unlimited talk and text, and six months of service for $60 upfront. That pencils out to $10 a month, before taxes and government surcharges, and it runs...

Continue Reading
Makers Nutrition Credit Puts a Clock on New Brands

Updated Category News Views 141

A few cents per bottle can look downright beautiful when a new supplement brand is staring at its first production bill. Makers Nutrition announced on November 17 a Black Friday manufacturing-credit offer aimed at entrepreneurs and established sellers launching a new formulation, with qualifying new orders eligible for as much as $0.45 per unit through November 29, 2026....

Continue Reading

Top 5 Most Recently Viewed Articles

Riyadh Gears Up for UNIDO 2025: A Step Towards Sustainable Industry

Updated Category News Views 180

Riyadh Gears Up for UNIDO 2025 Riyadh is on the verge of an exciting global event as it prepares to host the 21st Session of the United Nations Industrial Development Organization (UNIDO) General Conference. This significant summit is scheduled to happen at the King Abdulaziz International Conference Centre, where leaders from various sectors will gather to discuss the...

Continue Reading
Deer Park Road Strategizes for Growth Amid CRE Market Changes

Updated Category News Views 205

Deer Park Road Strategies in a Changing CRE Landscape Deer Park Road Management Company, LP, a notable $2.8 billion alternative asset management firm, is honing in on emerging prospects within the challenging environment of the Commercial Mortgage-Backed Securities (CMBS) market. The firm’s extensive expertise enables them to consistently identify potential value during...

Continue Reading
iRobot Corporation Faces Legal Challenges Amid Financial Struggles

Updated Category News Views 141

Legal Investigations into iRobot Corporation Investors are currently facing uncertainties surrounding iRobot Corporation as it faces legal scrutiny. The well-respected law firm Faruqi & Faruqi, LLP has initiated investigations regarding potential legal claims on behalf of investors who suffered significant losses. Who to Contact James (Josh) Wilson, a partner at Faruqi &...

Continue Reading
Dr. Andrea Fuyuko Honda Recognized for Medical Innovation Excellence

Updated Category News Views 385

Dr. Andrea Fuyuko Honda's Recent Recognition Dr. Andrea Fuyuko Honda has been prominently recognized as a Pinnacle Professional Member within an elite circle of excellence. This accolade reflects her significant contributions to the field as a Leading Medical Communications Expert and Innovator. With a career spanning over fifteen years, Dr. Honda has demonstrated...

Continue Reading
Centene Corporation Faces Securities Fraud Legal Action

Updated Category News Views 206

Centene Corporation Faces New Lawsuit Over Securities Fraud Investors of Centene Corporation, known by the ticker symbol CNC, have found themselves at the center of a securities fraud lawsuit. Recently, a leading law firm announced the initiation of legal action against Centene Corporation and some of its senior executives. This lawsuit stems from alleged violations of...

Continue Reading